Abstract: Surface modified particles have a core, an inner shell and an outer shell. The core is formed of silica or is hollow, the inner shell is formed by a layer of metal, and the outer shell is formed by a biocompatible polymer brush. The particles allow for direct optical detection of biomolecules such as nucleic acids, proteins, polysaccharides and glycoproteins in biological samples.

Abstract: Nanodiamonds having a positive ?-potential of at least 1 mV for use in sequestration of at least one FGF family member in organisms in vivo and in vitro. It has been found that nanodiamonds with a positive ?-potential show an extremely strong and selective binding to FGF family members, thus leading to their usability in the treatment of diseases related to aberrant FGF-FGFR signalling and/or interaction.

Abstract: The subject of the present invention is a lipidoid of general formula (I), wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfection particles containing this lipidoid, and their use.

Abstract: Various aspects according to the instant published patent application relate to a functionalized nanoscale diamond. The functionalized nanoscale diamond includes a functionalized surface. The functionalized surface includes a brominated portion and a hydroxylated portion. In further aspects, the brominated portion can be reacted with an amine to form an aminated nanoscale diamond.

Abstract: The present invention relates to a process for ion irradiation of a particulate substrate containing the steps of embedding particulate substrate in a solid matrix having 10B atoms, and exposing the matrix obtained in the previous step to a neutron flux to give irradiated particulate substrate. The process is extremely effective and amenable to large scale and is particularly suitable for producing irradiated nanodiamonds and irradiated SiC particles.

Abstract: Nanodiamonds having a positive ?-potential of at least 1 mV for use in sequestration of at least one FGF family member in organisms in vivo and in vitro. It has been found that nanodiamonds with a positive ?-potential show an extremely strong and selective binding to FGF family members, thus leading to their usability in the treatment of diseases related to aberrant FGF-FGFR signalling and/or interaction.

Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: Macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe, and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells. The targeting ligand may be attached to the synthetic copolymer via a flexible linker.

Abstract: Derivatives of boron cluster compounds of general formula I and their pharmaceutically acceptable salts and solvates, and their specific inhibition effect on the enzyme carbonic anhydrase IX, a protein overexpressed in cancer tissues. Methods of synthesis and the use of the novel derivatives. These inhibitors of human carbonic anhydrase IX can be used as active compounds of pharmaceuticals for diagnostics and/or therapy of cancer diseases.

Abstract: The invention concerns use of compounds of general formula Cu2SO3.MSO3.2H2O, in which M is Cu, Mn or Fe, for the protection of plants against fungal diseases. A method of protecting plants against fungal diseases and a pesticidal preparation including at least one compound of the general formula is also disclosed.

Abstract: Derivatives of boron cluster compounds of general formula I and their pharmaceutically acceptable salts and solvates, and their specific inhibition effect on the enzyme carbonic anhydrase IX, a protein overexpressed in cancer tissues. Methods of synthesis and the use of the novel derivatives. These inhibitors of human carbonic anhydrase IX can be used as active compounds of pharmaceuticals for diagnostics and/or therapy of cancer diseases.

Abstract: The invention relates to a liquid composition containing phosphoric or thiophosphoric triamide derivatives and suitable solvents selected from the group comprising esters of hydroxyacids, heterocyclic alcohols and their derivatives, cyclic carbonic acid esters and dicarboxyacid esters, optionally the composition may also contain glycol ethers and auxiliary substances. The invention further includes the use of this liquid composition as urease inhibitor in urea-containing fertilizers, in fertilizers and wastes of animal origin or in sprays masking animal urine odors.

Abstract: The invention relates to a liquid composition containing phosphoric or thiophosphoric triamide derivatives and suitable solvents selected from the group comprising esters of hydroxyacids, heterocyclic alcohols and their derivatives, cyclic carbonic acid esters and dicarboxyacid esters, optionally the composition may also contain glycol ethers and auxiliary substances. The invention further includes the use of this liquid composition as urease inhibitor in urea-containing fertilizers, in fertilizers and wastes of animal origin or in sprays masking animal urine odours.

Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.

Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.

Abstract: The invention relates to novel ecologically harmless non-toxic preparations containing plant stress hormones, their derivatives and titanium compounds, which after application by foliar spraying induce in whole intact plants the increase of the content of pharmacologically important secondary metabolites. High activity of these preparations was proved on the increase of contents of bioactive phenolic substances in the extract from the plant Echinacea purpurea L. (Moench.). Increase of the contents of the secondary metabolites in plants may be exploited in agriculture and pharmaceutical industry for the effective production of pharmacologically important substances.